Please assess the completion status of the following clinical trial:

Trial Title: FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 12 and 75 years of age, inclusive.~* Body weight at least 40 kg with a Body Mass Index \< 45~* PAH that is either idiopathic/heritable; associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); associated with collagen vascular disease; associated with HIV.~* Previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of PAH.~* Baseline 6-minute walk distance between 200 and 425 meters, inclusive.~* Reliable and cooperative with protocol requirements.~Exclusion Criteria:~* Nursing or pregnant.~* Currently receiving an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or prostacyclin within 30 days of Baseline.~* PAH due to conditions other than noted in the above inclusion criteria.~* History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.~* Use of an investigational drug within 30 days of Baseline.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- UT-15C (oral treprositnil) (Type: ACTIVE_COMPARATOR): Subjects receive UT-15C (oral treprostinil) twice daily.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects receive placebo (sugar pill) twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).